Techne’s stock price fell to $51.95. Shareholders have lost 13.8% of their capital, which is disappointing considering the ...

Earlier this week, Bio-Techne and Refeyn announced a first-of-its-kind integrated workflow that links Bio-Techne’s MauriceFlex™ icIEF fractionation system with Refeyn’s TwoMP mass photometry platform, ...

Bio‑Techne Corporation, a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in ...

The combined solutions support characterization capabilities for antibodies that cannot be achieved using standalone methods.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

While Bio-Techne has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Bio-Techne has announced a collaboration to distribute Spear Bio’s advanced SPEAR UltraDetect immunoassays worldwide, with an initial focus on the neurology research market. This partnership allows ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...

With a new name and a new CEO, Bio-Techne has begun an aggressive growth strategy to ensure that researchers know not only its flagship brand, R&D Systems, but the company as a whole. One year ago, ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...